Recursion Pharmaceuticals Q4 Earnings Report: What Investors Need to Know
Recursion Pharmaceuticals, Inc. Class A RXRX | 3.15 3.15 | +1.29% 0.00% Pre |
Recursion Pharmaceuticals (NASDAQ:RXRX) reported its Q4 earnings results on Wednesday, February 25, 2026 at 06:30 AM.
Here's what investors need to know about the announcement.
Earnings
Recursion Pharmaceuticals beat estimated earnings by 30.0%, reporting an EPS of $-0.21 versus an estimate of $-0.3.
Revenue was up $30.99 million from the same period last year.
Overview of Past Earnings
During the previous quarter, the company beat on EPS by $0.02, leading to a 6.85% drop share price change the next day.
Here's a look at Recursion Pharmaceuticals's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.38 | -0.35 | -0.52 | -0.42 |
| EPS Actual | -0.36 | -0.41 | -0.50 | -0.53 |
| Revenue Estimate | 18.60M | 14.98M | 18.08M | 19.04M |
| Revenue Actual | 5.17M | 19.22M | 14.74M | 4.55M |
To track all earnings releases for Recursion Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.